Moleculin Biotech Inc

NASDAQ:MBRX  
1.69
-0.03 (-1.74%)
Products

Moleculin Receives FDA Allowance To Begin A Phase 1 Study Of Wp1122 For Treatment Of Glioblastoma Multiforme

Published: 12/01/2021 13:55 GMT
Moleculin Biotech Inc (MBRX) - Moleculin Receives FDA Allowance to Begin a Phase 1 Study of Wp1122 for Treatment of Glioblastoma Multiforme.
Moleculin Biotech Inc - New US Ind Enables Parallel Development of Wp1122 As a Cancer Therapy.
Moleculin Biotech Inc - Believes Wp1122 Has Significant Potential As Both an Antiviral Therapy and As a Cancer Therapy.
Moleculin Biotech Inc - Intends to Seek Opportunities for an Investigator-initiated Clinical Trial of Wp1122 in Cancer Patients in 2022.
Further Company Coverage: Mbrxo ((reuters.
Briefs@thomsonreuters.
Com;)).